Ardent Health reclassifies former CEO’s exit as termination for cause

Ardent Health, Inc. (NYSE:ARDT) announced that its Board of Directors has recharacterized the June 2, 2026 departure of former President and Chief Executive Officer Martin J. Bonick as a termination for cause. The decision was made on Monday following a review and a hearing at which Mr. Bonick was given an opportunity to be heard.

The company stated that, after Mr. Bonick’s departure, it discovered facts and circumstances that would have allowed it to terminate his employment for cause as of the original separation date. According to the Board, Mr. Bonick failed to fully disclose compensation received from third parties, as required by company policies.

As a result of this determination, Ardent Health will discontinue the remaining severance payments and benefits previously agreed to under the June 26, 2026 Separation Agreement. This includes approximately $4.5 million in unpaid cash severance. Additionally, all outstanding unvested performance-based restricted stock units (PRSUs) granted to Mr. Bonick will be cancelled or forfeited. The company has also reserved its rights to pursue any other remedies against Mr. Bonick. According to InvestingPro analysis, the stock appears undervalued at current levels. For deeper insights, investors can access comprehensive Pro Research Reports covering ARDT and 1,400+ other US equities.

Ardent Health stated that no revisions or corrections are required for its previously disclosed financial statements or results in connection with these matters.

This information is based on a statement provided in a press release and disclosed in the company’s recent SEC filing.

In other recent news, Ardent Health Services reported its second-quarter 2026 earnings, revealing adjusted earnings of $0.12 per share, which fell short of the $0.17 forecast by analysts. Despite the earnings miss, the company generated strong cash flow and maintained its full-year outlook, with revenue reaching $1.62 billion. Following these results, several analyst firms adjusted their evaluations of the company. RBC Capital raised its price target for Ardent Health to $13.00 from $12.00, citing the company’s better-than-expected adjusted EBITDA for the quarter. Guggenheim also increased its price target to $14.00 from $13.00, highlighting improvements in surgery development and benefits from the IMPACT program. Meanwhile, BMO Capital initiated coverage of Ardent Health with a Market Perform rating and a price target of $11.00, noting the company’s new CEO’s focus on optimizing the existing footprint. These developments reflect the mixed reactions from analysts following the company’s latest financial results.